With a completed €40 million (US$43 million) investment in Slovenia, Novartis has opened its first specialized viral vector production facility in Europe, following earlier significant investments in ...
Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 million ($41.2 million) viral vector facility in Mengeš, Slovenia. The new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback